Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats.

Yang J, Wang Z, Fang Y, Jiang J, Zhao F, Wong H, Bennett MK, Molineaux CJ, Kirk CJ.

Drug Metab Dispos. 2011 Oct;39(10):1873-82. doi: 10.1124/dmd.111.039164. Epub 2011 Jul 13.

2.

Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.

Wang Z, Yang J, Kirk C, Fang Y, Alsina M, Badros A, Papadopoulos K, Wong A, Woo T, Bomba D, Li J, Infante JR.

Drug Metab Dispos. 2013 Jan;41(1):230-7. doi: 10.1124/dmd.112.047662. Epub 2012 Nov 1.

3.

The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.

Halpin RA, Geer LA, Zhang KE, Marks TM, Dean DC, Jones AN, Melillo D, Doss G, Vyas KP.

Drug Metab Dispos. 2000 Oct;28(10):1244-54.

4.

Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.

Egorin MJ, Lagattuta TF, Hamburger DR, Covey JM, White KD, Musser SM, Eiseman JL.

Cancer Chemother Pharmacol. 2002 Jan;49(1):7-19.

PMID:
11855755
5.

Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats.

Roumi M, Marleau S, du Souich P, Maggi T, Deghenghi R, Ong H.

Drug Metab Dispos. 2000 Jan;28(1):44-50.

6.

Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.

Fagerholm U, Breuer O, Swedmark S, Hoogstraate J.

J Pharm Pharmacol. 2005 May;57(5):587-97.

PMID:
15901348
7.
8.

Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats.

Paulson SK, Zhang JY, Breau AP, Hribar JD, Liu NW, Jessen SM, Lawal YM, Cogburn JN, Gresk CJ, Markos CS, Maziasz TJ, Schoenhard GL, Burton EG.

Drug Metab Dispos. 2000 May;28(5):514-21.

9.

Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.

Yamaguchi T, Nakajima Y, Mizobuchi M, Inazawa K, Kanazu T, Kadono K, Ohkawa T, Iwatani K.

Arzneimittelforschung. 1998 Oct;48(10):995-1006.

PMID:
9825117
10.

Pharmacokinetics and disposition of the novel dopamine agonist Z-7760 in rat after intravenous and oral administration.

Bollard M, Caldwell J, Taylor GW, Strolin-Benedetti M, Semeraro C.

Xenobiotica. 2000 Oct;30(10):983-91.

PMID:
11315106
11.

Pharmacokinetics and metabolism of a RAS farnesyl transferase inhibitor in rats and dogs: in vitro-in vivo correlation.

Singh R, Chen IW, Jin L, Silva MV, Arison BH, Lin JH, Wong BK.

Drug Metab Dispos. 2001 Dec;29(12):1578-87.

12.
13.
14.

Plasma pharmacokinetics and urinary and biliary excretion of a new potent tripeptide HIV-1 protease inhibitor, KNI-272, in rats after intravenous administration.

Kiriyama A, Fujita K, Takemura S, Kuramoto H, Kiso Y, Takada K.

Biopharm Drug Dispos. 1994 Oct;15(7):617-26.

PMID:
7849237
16.
17.

Pharmacokinetics, tissue distribution and excretion of vinflunine.

Zhao XP, Liu XQ, Wang YS, Wang H, Wang GJ.

Eur J Drug Metab Pharmacokinet. 2006 Apr-Jun;31(2):59-64.

PMID:
16898072
18.

Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats.

Lee SD, Lee WI, Shim HJ, Lee ED, Kim WB, Yang J, Kim CK, Lee MG.

J Clin Pharm Ther. 1996 Aug;21(4):201-13.

PMID:
8933293
19.

Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.

Leung KH, Cohn DA, Miller RR, Doss GA, Stearns RA, Simpson RE, Feeney WP, Chiu SH.

Drug Metab Dispos. 1996 Jul;24(7):753-60.

PMID:
8818572
20.

Pharmacokinetics, protein binding and metabolic profile of 3H-icometasone enbutate following intravenous, oral and intratracheal administrations to Sprague-Dawley rats.

Duchêne P, Giudicelli MD, Neau B, Gronfier A, Firmin Y, Villax P, Saivin S, Houin G.

Arzneimittelforschung. 1998 Apr;48(4):371-8.

PMID:
9608879

Supplemental Content

Support Center